

COMPANY OVERVIEW

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory and pharma services company that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics. Headquartered in Fort Myers, FL, NeoGenomics maintains a network of testing facilities across the US. NeoGenomics services the needs of pathologists, oncologists, urologists and other physician specialists, academic institutions, and the pharmaceutical industry.

NeoGenomics Schedules its First Quarter Earnings Release for May 1, 2018

Apr 2 2018, 5:00 PM EDT

NeoGenomics Announces Executive Appointments

Mar 20 2018, 7:00 AM EDT

NeoGenomics Reports Revenue of \$67.8 Million on 18.7% Clinical Volume Growth and \$10.5 Million of Adjusted EBITDA in the Fourth Quarter of 2017

Feb 21 2018, 7:00 AM EST

STOCK OVERVIEW

Symbol NEO
Exchange NASDAQ
Shares OS 80,507,094
Market Cap \$746.3M
Last Price \$9.27

52-Week \$7.08 - \$11.63

Range

INVESTOR RELATIONS

William Bonello
Vice President, Strategy,
Corporate Development and
Investor Relations
T: (239) 690-4238
M: (239) 284-4314
bill.bonello@neogenomics.com

MANAGEMENT TEAM

Douglas M. VanOort

Chairman of the Board of Directors and Chief Executive Officer

Maher Albitar, M.D.

Senor Vice President, Chief Medical Officer and Director of Research and Development

Jennifer Balliet

Vice President and Chief Culture Officer

William Bonello

Vice President, Strategy, Corporate Development and Investor Relations

Steven G. Brodie, Ph.D.

Vice President of Operations

George A. Cardoza

President, Pharma Services Division

Steven C. Jones

Executive Vice President and Board Member

Denise E. Pedulla

General Counsel

Steven A. Ross

Vice President, Chief Information Officer

Robert J. Shovlin

President, Clinical Services Division

Sharon Virag

Chief Financial Officer

NEOGENOMICS, INC.

12701 Commonwealth Dr. Suite 9 Fort Myers, FL 33913

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and it's quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.